Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H20ClNO.ClH |
Molecular Weight | 350.282 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12CCC3=CC=CC=C3[C@]1([H])C4=CC(O)=C(Cl)C=C4CCN2C
InChI
InChIKey=APFMVAHRFWBCDG-JUOYHRLASA-N
InChI=1S/C19H20ClNO.ClH/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21;/h2-5,10-11,17,19,22H,6-9H2,1H3;1H/t17-,19+;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H20ClNO |
Molecular Weight | 313.821 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ecopipam (SCH-39166) is a selective D1 dopamine receptor antagonist both in vitro and in vivo. Additionally, it exhibits saturable, high-affinity binding to D5 receptors. Ecopipam was studied clinically for a variety of indications, including schizophrenia, drug abuse, and obesity, but in each case undesirable effects were observed. Currently, ecopipam is in clinical trials for the treatment of Lesch-Nyhan and Gilles de la Tourette's syndromes.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. | 1991 Apr 18 |
|
Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. | 1994 Nov |
|
Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. | 1995 Feb |
|
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. | 1997 May |
|
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). | 1999 Dec |
|
Altered activity of midbrain dopamine neurons following 7-day withdrawal from chronic cocaine abuse is normalized by D2 receptor stimulation during the early withdrawal phase. | 1999 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01065558
Phase I study of safety and tolerability of ecopipam in patients with Lesch-Nyhan disease: Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:42:40 GMT 2023
by
admin
on
Fri Dec 15 16:42:40 GMT 2023
|
Record UNII |
5X1J3190JI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
284109
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
||
|
FDA ORPHAN DRUG |
308210
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
||
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
||
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL298406
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
5X1J3190JI
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
DTXSID50172488
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
C87494
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
JJ-92
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
170317
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
SUB128274
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
190133-94-9
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
100000153825
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY | |||
|
DBSALT002167
Created by
admin on Fri Dec 15 16:42:40 GMT 2023 , Edited by admin on Fri Dec 15 16:42:40 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |